Cargando…

Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci

The genus Enterococcus comprises a ubiquitous group of Gram-positive bacteria that can cause diverse health care-associated infections. Their genome plasticity enables easy acquisition of virulence factors as well as antibiotic resistances. Urinary tract infections (UTIs) and catheter-associated UTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Montalbán-López, Manuel, Cebrián, Rubén, Galera, Rosa, Mingorance, Lidia, Martín-Platero, Antonio M., Valdivia, Eva, Martínez-Bueno, Manuel, Maqueda, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558097/
https://www.ncbi.nlm.nih.gov/pubmed/32887311
http://dx.doi.org/10.3390/antibiotics9090567
_version_ 1783594563970007040
author Montalbán-López, Manuel
Cebrián, Rubén
Galera, Rosa
Mingorance, Lidia
Martín-Platero, Antonio M.
Valdivia, Eva
Martínez-Bueno, Manuel
Maqueda, Mercedes
author_facet Montalbán-López, Manuel
Cebrián, Rubén
Galera, Rosa
Mingorance, Lidia
Martín-Platero, Antonio M.
Valdivia, Eva
Martínez-Bueno, Manuel
Maqueda, Mercedes
author_sort Montalbán-López, Manuel
collection PubMed
description The genus Enterococcus comprises a ubiquitous group of Gram-positive bacteria that can cause diverse health care-associated infections. Their genome plasticity enables easy acquisition of virulence factors as well as antibiotic resistances. Urinary tract infections (UTIs) and catheter-associated UTIs are common diseases caused by enterococci. In this study, Enterococcus strains isolated from UTIs were characterized, showing that the majority were E. faecalis and contained several virulence factors associated to a better colonization of the urinary tract. Their susceptibility against the bacteriocin AS-48 and several antibiotics was tested. AS-48 is a potent circular bacteriocin that causes bacterial death by pore formation in the cell membrane. The interest of this bacteriocin is based on the potent inhibitory activity, the high stability against environmental conditions, and the low toxicity. AS-48 was active at concentrations below 10 mg/L even against antibiotic-resistant strains, whereas these strains showed resistance to, at least, seven of the 20 antibiotics tested. Moreover, the effect of AS-48 combined with antibiotics commonly used to treat UTIs was largely synergistic (with up to 100-fold MIC reduction) and only occasionally additive. These data suggest AS-48 as a potential novel drug to deal with or prevent enterococcal infections.
format Online
Article
Text
id pubmed-7558097
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75580972020-10-22 Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci Montalbán-López, Manuel Cebrián, Rubén Galera, Rosa Mingorance, Lidia Martín-Platero, Antonio M. Valdivia, Eva Martínez-Bueno, Manuel Maqueda, Mercedes Antibiotics (Basel) Article The genus Enterococcus comprises a ubiquitous group of Gram-positive bacteria that can cause diverse health care-associated infections. Their genome plasticity enables easy acquisition of virulence factors as well as antibiotic resistances. Urinary tract infections (UTIs) and catheter-associated UTIs are common diseases caused by enterococci. In this study, Enterococcus strains isolated from UTIs were characterized, showing that the majority were E. faecalis and contained several virulence factors associated to a better colonization of the urinary tract. Their susceptibility against the bacteriocin AS-48 and several antibiotics was tested. AS-48 is a potent circular bacteriocin that causes bacterial death by pore formation in the cell membrane. The interest of this bacteriocin is based on the potent inhibitory activity, the high stability against environmental conditions, and the low toxicity. AS-48 was active at concentrations below 10 mg/L even against antibiotic-resistant strains, whereas these strains showed resistance to, at least, seven of the 20 antibiotics tested. Moreover, the effect of AS-48 combined with antibiotics commonly used to treat UTIs was largely synergistic (with up to 100-fold MIC reduction) and only occasionally additive. These data suggest AS-48 as a potential novel drug to deal with or prevent enterococcal infections. MDPI 2020-09-02 /pmc/articles/PMC7558097/ /pubmed/32887311 http://dx.doi.org/10.3390/antibiotics9090567 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Montalbán-López, Manuel
Cebrián, Rubén
Galera, Rosa
Mingorance, Lidia
Martín-Platero, Antonio M.
Valdivia, Eva
Martínez-Bueno, Manuel
Maqueda, Mercedes
Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
title Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
title_full Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
title_fullStr Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
title_full_unstemmed Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
title_short Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
title_sort synergy of the bacteriocin as-48 and antibiotics against uropathogenic enterococci
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558097/
https://www.ncbi.nlm.nih.gov/pubmed/32887311
http://dx.doi.org/10.3390/antibiotics9090567
work_keys_str_mv AT montalbanlopezmanuel synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci
AT cebrianruben synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci
AT galerarosa synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci
AT mingorancelidia synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci
AT martinplateroantoniom synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci
AT valdiviaeva synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci
AT martinezbuenomanuel synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci
AT maquedamercedes synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci